Statement of Principles concerning malignant neoplasm of the oesophagus (Balance of Probabilities) (No. 12 of 2026)

The instrument operates on several key concepts defined either in the body or in the Schedule 1 dictionary. “Malignant neoplasm of the oesophagus” is the central condition. It uses ICD-10-AM code C15 as an aid but the operative definition is in subsection 7(2): primary malignant neoplasms arising from cells of the oesophagus, proximal border being the lower hypopharynx, distal border the lower oesophageal sphincter, including the gastro-oesophageal junction. This definition excludes soft tissue sarcoma, carcinoid tumour, and lymphomas, which are covered by separate SoPs. “Death from malignant neoplasm of the oesophagus” includes death contributed to by a terminal event (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function). This means the SoP extends to cases where the cancer is a contributing cause, not solely the immediate cause.

“Relevant service” is defined by reference to VEA and MRCA categories that are not operational or hazardous service. Specifically, it means eligible war service (other than operational service), defence service (other than hazardous service and British nuclear test defence service), and peacetime service under MRCA. This limits the SoP to a subset of military service; for operational or hazardous service, a different standard of proof (reasonable hypothesis) and separate SoPs may apply. The instrument is made under subsection 196B(3) (balance of probabilities) only, not the reasonable hypothesis standard.

The factors themselves rely on several quantified thresholds. “Pack-year” is defined as 20 cigarettes per day for one year, or 7,300 grams of tobacco by weight. This allows conversion for pipe and cigar smokers. For smoking, the required dose is at least 5 pack-years before clinical onset, and if smoking has ceased, clinical onset must occur within 15 years of cessation. “Cumulative equivalent dose” uses the ARPANSA methodology from 2 August 2017, and the factor requires at least 0.5 sievert to the oesophagus, at least 10 years before clinical onset. Asbestos exposure is broken into enclosed space (2,000 hours cumulative) and open environment (6,000 hours cumulative), with the exposure occurring during application, removal, etc., and first inhalation at least 10 years before onset.

Alcohol consumption is measured in kilograms: at least 250 kilograms before clinical onset, with each standard drink containing 10 grams. This equates to roughly 25,000 standard drinks. Maté drinking and betel quid chewing require use on more days than not for at least 10 years, with a 10-year window after cessation. Processed meat product is defined (ham, frankfurters, salami, bacon) and requires an average daily intake of at least 25 grams for at least 10 years within the 25 years before clinical onset. The “inability to obtain appropriate clinical management” factor applies only to clinical worsening, not initial onset, and requires that the malignant neoplasm was suffered or contracted before or during (but not arising out of) the person’s relevant service, making it an aggravation factor.

The primary affected groups are Australian veterans and members of the Forces who have rendered “relevant service” as defined, and who subsequently develop malignant neoplasm of the oesophagus or die from it. This includes persons who performed eligible war service (non-operational), defence service (non-hazardous), or peacetime service under the MRCA. Their dependants are also affected indirectly through claims for dependent’s benefits following death. The instrument applies to all claims under VEA section 120B or MRCA section 339 that are lodged after its commencement or pending at commencement (the application provision does not limit it to new claims only). Therefore, any existing claim not yet finally determined that falls within these statutory sections must be assessed under this SoP.

The Repatriation Medical Authority (RMA) is the determinant; its members are medical experts who determine the factors based on sound medical-scientific evidence. The RMA is bound by its own instrument but has the power to revoke or replace it. The Repatriation Commission and the Military Rehabilitation and Compensation Commission are the primary decision-makers who must apply the SoP. They must ensure that their medical officers and delegates are familiar with its contents, especially the subtype-specific factors and the technical definitions (e.g., cumulative equivalent dose calculation). Legal representatives for claimants and for the Commissions must advise on the application of the factors, including the interaction with other SoPs via section 11.

Medical practitioners who provide evidence for claims are affected because they need to tailor their reports to the SoP’s requirements: specifying histological subtype, calculating pack-years, estimating alcohol intake in kilograms, documenting GERD duration, calculating obesity periods, and identifying evidence of Barrett oesophagus or other pre-existing conditions. The instrument imposes a burden on experts to apply the ARPANSA dose method and to assess asbestos exposure hours. The dictionary definitions of “processed meat product” and “smokeless tobacco” also require precise categorisation of dietary and tobacco habits. The instrument creates a standardised framework that can simplify some claims (if a factor is clearly met) but adds complexity for those requiring detailed reconstruction of past exposures. The cost of complying with the evidence requirements falls disproportionately on claimants who may lack service records or medical history to prove the specific thresholds.

The SoP does not impose duties on claimants directly; rather, it codifies the evidentiary conditions the decision-maker must be satisfied of before granting a claim. The operative duty lies on the Repatriation Commission or MRCC to apply the SoP when determining whether the disease is connected to relevant service on the balance of probabilities. This duty arises from VEA section 120B and MRCA section 339. The decision-maker must find that at least one factor in section 9 exists and that the factor is related to the person’s relevant service. The decision-maker does not have discretion to accept a connection on other medical grounds not listed in the instrument, unless the claim is made under a different standard of proof (reasonable hypothesis) using a different SoP. Therefore, the SoP creates a right in the claimant to have their claim assessed against this checklist, but also a limitation: if no factor fits, the claim will fail, irrespective of other medical evidence.

The RMA has the duty to determine the SoP based on sound medical-scientific evidence (section 8). The instrument states that the RMA is of the view that it is more probable than not that the disease can be related to relevant service. This is a statutory opinion, not a legal conclusion. The RMA also has a duty to keep SoPs current; the repeal of the 2015 SoP and replacement with this 2026 version reflects that duty. Section 11 imposes a duty to read the SoP together with other SoPs: if a factor references a disease covered by another SoP (e.g., Barrett oesophagus, Plummer-Vinson syndrome), then the factors of that other SoP apply as in force from time to time. This means a claim may require satisfaction of multiple SoPs simultaneously, increasing the compliance burden.

Claimants have the right to present evidence showing that one of the factors exists and is service-related. They also have the right to seek internal review and merits review (through the Veterans’ Review Board and the Administrative Appeals Tribunal) and judicial review for jurisdictional error. However, the SoP is a legislative instrument binding on the review bodies. The instrument itself does not grant any new appeal rights; it merely supplies the substantive rule that the review body must apply. The “inability to obtain appropriate clinical management” factor creates a narrow right to claim for worsening of a condition that pre-existed service, but only if the inability is related to service (e.g., due to military posting preventing access to treatment). That factor is explicitly limited to material contribution to, or aggravation of, the condition.

The SoP is not a penal instrument. It carries no criminal penalties, fines, or imprisonment. Its enforcement mechanism is through the administrative law system. If the decision-maker fails to apply the SoP correctly, the claim may be refused, and the claimant can challenge that refusal. Conversely, if the decision-maker applies the SoP incorrectly to grant a claim, there is limited scope for the Commonwealth to claw back amounts, though overpayments can be recovered under the VEA. The instrument itself is not subject to prosecution. However, making a false or misleading statement in support of a claim (e.g., falsifying pack-year history or asbestos exposure hours) may attract penalties under the Criminal Code (section 137.1 for providing false information to a Commonwealth entity) or under the VEA for making a false statement in a claim. These penalties apply generally, not specifically because of the SoP.

The SoP is binding on the decision-maker. If a review body finds that the decision-maker misapplied the SoP (e.g., misread the definition of malignant neoplasm, or applied a factor to the wrong histological subtype), the decision will be set aside and remitted. There is no direct penalty for the decision-maker, but consistent errors could lead to systemic oversight by the Commonwealth Ombudsman or the Administrative Review Council. The RMA’s determination is subject to judicial review only on limited grounds such as jurisdictional error or failure to follow the legislative process (e.g., not having sound medical-scientific evidence). However, the courts afford substantial deference to the RMA’s medical-scientific assessment. The practical enforcement risk is borne by the claimant: if they cannot fit within the factors, their claim fails, and they bear the cost of that failure.

The instrument also has an indirect enforcement effect on medical experts. While not penal, an expert who consistently provides reports that are inconsistent with the SoP’s definitions (e.g., describing lymphoma as oesophageal cancer) may lose credibility with the Commission. The Commission may require evidence to be directed at the specific factor thresholds. Overall, the SoP reduces enforcement costs by making causation assessments more objective and less reliant on contested medical opinion, but it increases the cost of gathering evidence to meet the strict thresholds.

The SoP is made under VEA Part XIA, specifically subsection 196B(3). It operates as a legislative instrument under the Legislation Act 2003. It is subject to disallowance by either House of Parliament, though the RMA often relies on the exemption for certain medical determinations. The SoP must be read with VEA section 120B, which provides that the Commission must determine a claim for a disease consistent with the relevant SoP. Similarly, MRCA section 339 imposes the same requirement. The SoP does not apply to claims under the Safety, Rehabilitation and Compensation Act 1988 or other workers’ compensation schemes for Australian Defence Force members; those are separate regimes. However, the definitions in the SoP may be adopted by analogy in other contexts.

The SoP interacts with the International Statistical Classification of Diseases (ICD-10-AM) for coding purposes, but the operative definition is the medical description in subsection 7(2), not the ICD code. This means a person with a tumour at the gastro-oesophageal junction may be classified as C15 (oesophagus) or C16 (stomach); the SoP covers those that arise from oesophageal cells, which may require histology to determine. The dictionary defines “cumulative equivalent dose” by reference to an ARPANSA guide as in force on 2 August 2017. Any subsequent amendment to that guide does not automatically update the SoP; only the RMA can change it. This creates potential inconsistency if the ARPANSA methodology is revised.

Section 11 is a key interaction provision: if a factor refers to an injury or disease covered by another SoP, the factors of that other SoP apply as in force from time to time. This means that the SoP for malignant neoplasm of the oesophagus incorporates by reference other SoPs (e.g., SoP for Barrett oesophagus, SoP for gastro-oesophageal reflux disease, SoP for Plummer-Vinson syndrome, SoP for Chagas disease). The claimant must satisfy the applicable SoP for each referenced condition. For example, to satisfy factor 9(13) (Barrett oesophagus before clinical onset), the person must meet the definition and factor requirements of the SoP for Barrett oesophagus. If that SoP is amended, the requirements change automatically. This creates a dynamic compliance framework where the claimant’s evidence must track multiple instruments.

The SoP also interacts with the general law of evidence. The balance of probabilities standard applies. Where the instrument uses terms like “clinical onset”, that is a medical concept not defined in the SoP; its meaning is drawn from general medical dictionary usage and case law. The instrument does not override the common law on causation; it provides a statutory shortcut for service-related claims. Outside the military compensation context, the SoP has no legal effect.

This instrument, Statement of Principles concerning malignant neoplasm of the oesophagus (Balance of Probabilities) (No. 12 of 2026), was made on 19 December 2025 and commences on 19 January 2026. It repeals the 2015 SoP (No. 121 of 2015). The 2015 SoP was made under both subsections 196B(3) and (8) of the VEA, meaning it covered both the balance of probabilities standard and the reasonable hypothesis standard for the same disease. The 2026 SoP is made solely under subsection 196B(3) (balance of probabilities). The repeal of the 2015 SoP suggests that the RMA either determined that a separate reasonable hypothesis SoP should exist (which would be a different instrument, not provided here) or that the balance-of-probabilities factors are now considered sufficient for both standards. However, the instrument does not state that a separate reasonable hypothesis SoP has been made. This change may affect claims where the reasonable hypothesis standard applies (operational service, hazardous service). Those claims may now require a different SoP, which may not exist yet, creating a gap. Typically, the RMA releases both types simultaneously. The fact that only the balance-of-probabilities version is before us suggests the reasonable hypothesis SoP may be a separate instrument (No. 11 of 2026 or similar), but we cannot assume from this source.

The factors differ from the 2015 SoP. While we do not have the 2015 text, the 2026 version adds several new factors not present in older SoPs for this disease: processed meat product consumption (factor 15), betel quid or areca nut chewing (factor 14), and Chagas megaesophagus (factor 16). These reflect updated epidemiological evidence. The factor for inability to obtain appropriate clinical management (factor 17) was also likely present in the 2015 version but may have been amended. The definitions have been updated: the current dictionary includes a specific note for pack-year equivalence and a reference to the ARPANSA guide dated 2 August 2017 (previously may have been an older date). The instrument also now contains an explicit note under definitions for “processed meat product” and “smokeless tobacco”, providing greater clarity.

The commencement delay (26 days from making to commencement) is standard to allow the Commission to update its guidelines. The repeal clause (section 4) ensures that only this SoP applies from 19 January 2026. Any pending claims are determined under the new SoP because the instrument applies to claims to which section 120B or section 339 applies, without transitional provisions that would preserve the old SoP for pre-existing claims. This could disadvantage claimants who had prepared their case under the 2015 factors if the new factors are stricter (e.g., higher pack-year threshold for smoking, which remains at 5 pack-years in the 2026 version, but note the smoking cessation window remains 15 years). However, the addition of new factors could also benefit some claimants by expanding the basis for connection.

The source document contains no information about any litigation concerning the 2015 SoP or this 2026 SoP. Statements of Principles generally have been the subject of litigation in the Veterans’ Review Board, the Administrative Appeals Tribunal, and the Federal Court. Common issues include interpretation of “clinical onset”, whether a factor is service-related, and whether the RMA had sound medical-scientific evidence for a particular factor. For malignant neoplasm of the oesophagus specifically, there may have been cases discussing the 15-year cessation window for smoking or the 250-kilogram alcohol threshold. However, we cannot cite those cases from this source alone.

The absence of litigation history in the instrument is expected; SoPs are legislative instruments that are rarely challenged directly on their face. Challenges are typically made in the context of individual claim refusals, where the applicant argues that the SoP is invalid or should not apply. The Federal Court has held that SoPs are binding and that the RMA has a wide discretion in determining factors. The 2026 SoP may face future litigation if a claimant argues that a factor is not supported by sound medical-scientific evidence (e.g., the processed meat factor, which is a relatively new inclusion). However, the instrument itself states that the RMA is of the view that the factors are supported, and courts generally accept the RMA’s assessment.

The instrument’s interaction with other SoPs via section 11 could also generate litigation if there is a conflict between SoPs or ambiguity in incorporation. For example, if the Barrett oesophagus SoP is amended, a claimant may argue that the earlier version applied. The note in section 11 says “as in force from time to time”, meaning the current version applies. This could be challenged but is likely valid under the Legislation Act.

Several traps lurk in the instrument’s definitions and structure. First, the exclusion clause: malignant neoplasm of the oesophagus does not include soft tissue sarcoma, carcinoid tumour, non-Hodgkin lymphoma, or Hodgkin lymphoma. A pathology report describing “lymphoma of the oesophagus” would be outside the SoP, and the claim would need a different SoP (e.g., SoP for non-Hodgkin lymphoma). This is easy to overlook if the tumour site is the oesophagus. Second, the split factors by histological subtype are critical. If the pathology does not specify the subtype, or if it is “undifferentiated carcinoma”, the factor must be matched: some factors apply only to squamous cell/undifferentiated (alcohol, maté, Plummer-Vinson), some only to adenocarcinoma/undifferentiated (GERD, obesity, Barrett). For undifferentiated carcinoma, the more restrictive set applies; the claimant cannot mix and match. For example, an undifferentiated carcinoma patient with obesity cannot rely on the obesity factor because it is adenocarcinoma-only, yet the note says for “adenocarcinoma or undifferentiated carcinoma”, so undifferentiated is covered for those factors. But check factor 11: it says “for adenocarcinoma or undifferentiated carcinoma of the oesophagus only” (GERD, obesity, Barrett). And factor 8 says “for squamous cell or undifferentiated carcinoma of the oesophagus only” (alcohol, Plummer-Vinson, maté). So undifferentiated can use either set, but only one factor needs to exist. However, the claimant cannot combine a squamous-cell-specific factor with an adenocarcinoma-specific factor if the type is known. Error in diagnosis could lead to a failed claim.

The timing thresholds are another gotcha. For smoking, clinical onset must be within 15 years of cessation. If a person stopped smoking 20 years before diagnosis, the smoking factor alone cannot succeed unless they smoked after cessation (impossible). They would need another factor. For processed meat, the 10-year consumption period must be within the 25 years before clinical onset, not cumulative over a lifetime. So a person who ate bacon daily for 20 years but stopped 30 years ago fails. For alcohol, the 250 kilograms must be before clinical onset; there is no look-back period, but the amount is high: 250 kg = 25,000 standard drinks = approximately 10 standard drinks per day for 7 years, or 5 per day for 14 years. Many heavy drinkers may not reach that. The obesity factor requires a BMI of 30 or greater for at least 10 years in the 20 years before clinical onset. Weight fluctuations can make this hard to prove.

The “inability to obtain appropriate clinical management” factor (17) is only for clinical worsening, not for initial onset. It also requires that the malignant neoplasm was suffered or contracted before or during (but did not arise out of) the person’s relevant service. This is an aggravation factor for existing conditions. Many claimants may mistakenly try to use it for initial onset. Moreover, the factor must be related to service: the inability must arise from the circumstances of service (e.g., being deployed to a remote area without medical facilities). A general claim that the claimant could not afford treatment would not be service-related.

The dictionary definition of “relevant service” excludes operational service and hazardous service. This means the SoP applies to a limited category: non-operational eligible war service (e.g., service in Australia during wartime), defence service not involving hazardous duty, and peacetime service under MRCA. For operational service claims, the standard is reasonable hypothesis, and a separate SoP (likely No. 11 of 2026, not provided) would apply. Using this SoP for an operational service claim would be a jurisdictional error. Similarly, the note for cumulative equivalent dose says examples include diagnostic medical procedures. But if the exposure occurred during service (e.g., medical x-rays), that may be service-related. However, the ARPANSA methodology must be used, and the dose must be to the oesophagus, not whole body. This requires expert reconstruction.

For the Repatriation Commission and MRCC, compliance means having procedures to check each claim against the factors. The decision-maker must identify the histological subtype from pathology reports. If no subtype is given, request it. Then, for each factor, verify the dose or exposure against the thresholds. For smoking, convert cigarette, pipe, and cigar use into pack-years using the formula. If the person smoked 10 cigarettes per day for 10 years, that is 5 pack-years (10/20 * 10). Check cessation window. For asbestos, determine whether exposure was in an enclosed or open environment and count total hours; ensure first inhalation was at least 10 years before onset. For alcohol, calculate total kilograms: each standard drink is 10 grams, so 250 kg is 25,000 drinks. Document the period of consumption. For processed meat, verify that the person consumed an average of at least 25 grams per day for at least 10 years within the 25 years before onset. This may require dietary history. For obesity, obtain height and weight records to show BMI of 30 or greater for at least 10 years in the 20-year window.

The “inability to obtain appropriate clinical management” factor (17) requires a two-step check: first, the cancer was suffered or contracted before or during (but not arising out of) service. This means the person already had the disease before service or developed it during service from a non-service cause. Second, the inability to obtain appropriate clinical management contributed to clinical worsening. The decision-maker must find that the inability was related to service (e.g., lack of access due to posting). The person must also satisfy the other factors if this is the sole factor? Section 10(2) says this factor applies only to material contribution to or aggravation. It does not require another factor; it stands alone but only for worsening.

For claimants and their legal representatives, compliance means gathering documentary evidence for the chosen factor. Obtain service records that show smoking history (e.g., ration pack cigarette records? Usually not available; rely on self report corroborated by medical records). For alcohol intake, medical records may mention abuse. For obesity, health records. For asbestos, service records of posting to ships or buildings with asbestos. The ARPANSA guide must be used for radiation claims; a medical physicist may need to calculate dose. Claimants should not assume a factor is satisfied without precise quantification. If the subtype is undifferentiated, they can use either set of factors, but should choose the easiest to prove. They should also be aware that a factor that refers to another disease (e.g., Barrett oesophagus) requires meeting the SoP for that disease. They should request the current SoP for that disease and ensure compliance.

The Commission should train its staff on the dictionary definitions, especially “processed meat product” (ham, bacon, salami, frankfurters but not fresh meat), “smokeless tobacco” (chewing tobacco, snuff, not nicotine pouches?), and “cumulative equivalent dose” (calculated as per ARPANSA guide). Review bodies (VRB, AAT) must apply the same criteria. The instrument does not provide for exceptions, so strict compliance is required. If a claimant clearly has oesophageal cancer from a known cause not listed, the only recourse is to argue that the SoP is invalid (unlikely to succeed) or lobby the RMA for amendment. The uptake factor for the new processed meat factor may increase claims from veterans with long-term dietary habits, but the evidence burden is high.

The instrument commences on 19 January 2026. Any claim finalised after that date must use this SoP. Claimants with pending claims should check if their chosen factor is still valid and whether new factors could help. The repeal of the 2015 SoP means that if the 2015 version had a less stringent threshold for a factor (e.g., lower asbestos hours), the new stricter threshold applies. There is no saving provision. Therefore, claimants who would have succeeded under the 2015 SoP may now fail. Conversely, new factors may allow previously unsuccessful claims to be reopened. Because of the strictness, getting expert legal and medical advice specifically tailored to the SoP is essential.